Human hematopoietic stem and progenitor cell antigen and methods for its use

• US 20010051372A1
• Filed: 06/13/2001
• Published: 12/13/2001
• Est. Priority Date: 04/26/1996
• Status: Abandoned Application

• Current Assignee: Amy H. Yin, David W. Buck, Sheri Miraglia, Wayne G. Godfrey
• Original Assignee: Amy H. Yin, David W. Buck, Sheri Miraglia, Wayne G. Godfrey
• Inventors: Miraglia, Sheri, Godfrey, Wayne G., Buck, David W., Yin, Amy H.
• Application Number:
  US09/881,853
• Publication Number:
  US 20010051372A1
• Time in Patent Office: Days
• US Class Current: 435/325
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: G01N 33/56966 Animal cells
• CPC Class Codes: Y10S 530/806 Antigenic peptides or proteins
• CPC Class Codes: Y10S 530/838 Marrow; spleen

Abstract

A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34^bright and contains substantially all of the CFU-GM activity present in the CD34⁺ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.

Claims

1. An antibody that specifically binds to AC133 antigen.

2. An antibody according to

claim 1

, wherein said antibody is a monoclonal antibody produced by a hybridoma cell line.

3. A monoclonal antibody according to

claim 2

, wherein said antibody blocks simultaneous binding to said antigen by the antibody produced by the hybridoma cell line ATCC.

4. A monoclonal antibody according to

claim 1

, wherein said antibody is induced through contralateral immunization.

5. A monoclonal antibody according to

claim 1

, produced by the hybridoma cell line ATCC ______.

6. A method for enrichment of hematopoietic stem or progenitor cells or both, said method comprising:

combining a mixed population of human cells comprising hematopoietic stem or progenitor cells or both with a reagent that specifically binds to the hematopoietic progenitor cell antigen recognized by the antibody produced by the hybridoma cell line ATCC ______; and

selecting for those cells that bind said reagent;

wherein said selected cells are enriched in hematopoietic stem or progenitor cell activity or both, depending on whether said mixed popluation of human cells contained hematopoietic stem or progenitor cells or both, respectively.

7. A method according to

claim 6

, further comprising:

combining said mixed population of human cells with a reagent that specifically recognize at least one of the cell surface markers CD90, CDll 7 and HLA-DR; and

selecting for those cells that are positive for said at least one of said cell surface markers.

8. A method according to

claim 6

, wherein said reagent is an antibody or an antibody mixture.

9. A method according to

claim 8

, wherein at least one of said antibodies is fluorochrome conjugated.

10. A method according to

claim 9

, wherein said selecting with said fluorochrome conjugated antibodies is by flow cytometry.

11. A method according to

claim 8

, wherein at least one of said antibodies is conjugated to magnetic particles.

12. A method according to

claim 11

, wherein said selecting with said magnetic particle conjugated antibodies is by high gradient magnetic selection.

35. A method for identifying a ligand that binds to human hematopoetic stem cells, comprising detecting binding of said ligand with the polypeptide of

claim 8

,.

13. A substantially pure population of hematopoietic progenitor cells, wherein said cells are bound to a reagent that specifically binds to the hematopoietic progenitor cell antigen recognized by the antibody produced by the hybridoma cell line ATCC HB12346.

14. A substantially pure population of hematopoietic progenitor cells according to

claim 13

, wherein said reagent is a monoclonal antibody.

15. A substantially pure population of hematopoietic progenitor cells according to

claim 14

, wherein said monoclonal antibody is produced by the hybridoma cell line ATCC HB12346.

16. A substantially pure population of hematopoietic progenitor cells according to

claim 15

, wherein said progenitor cells are obtained from human fetal liver.

17. A substantially pure population of hematopoietic progenitor cells according to

claim 15

, wherein said progenitor cells are obtained from human peripheral blood.

18. A substantially pure population of hematopoietic progenitor cells according to

claim 15

, wherein said progenitor cells are obtained from human bone marrow.

19. A substantially pure population of hematopoietic progenitor cells according to

claim 18

, wherein said bone marrow is adult.

20. A substantially pure population of hematopoietic progenitor cells according to

claim 18

, wherein said bone marrow is fetal.

21. An isolated nucleic acid molecule, wherein said molecule comprises:

(1) a first sequence having an amino acid coding region for AC133 as set forth in FIG. 12 (SEQ ID NO;

1);

(2) a second sequence, wherein said second sequence is a subsequence of said first sequence and is at least 14 nucleotides in length;

(3) a third sequence in which at least one nucleotide of said first or second sequences is replaced by a different nucleotide;

or

(4) a fourth sequence complementary to any of said first, second or third sequences;

with the proviso that (i) if said molecule is an RNA molecule, U replaces T in said sequence of said molecule, (ii) said third sequence is at least 90% identical to said first or second sequence, and (iii) said second sequence is not nucleotides 347-667, 1564-1696, or 2010-2386 of SEQ ID NO;

1.

22. The isolated molecule of

claim 21

, wherein said molecule comprises said first sequence.

23. The isolated molecule of

claim 21

, wherein said molecule comprises said second sequence.

24. The isolated molecule of

claim 21

, wherein said molecule comprises said third sequence.

25. The isolated molecule of

claim 21

, wherein said molecule consists essentially of DNA encoding the amino acid sequence of AC133.

26. An expression vector comprising a nucleic acid sequence of

claim 21

.

27. A cell transfected with the molecule of

claim 26

.

28. An isolated polypeptide, wherein said polypeptide comprises:

(1) a first amino acid sequence of AC133 as set forth in SEQ ID NO;

2;

(2) a second amino acid sequence wherein said second sequence is a subsequence of said first sequences and is at least 6 amino acids in length;

or (3) a third sequence in which at least one amino acid of said first or second sequences is replaced by a different amino acid, with the proviso that said amino acid replacement is a replacement of one acidic residue for another, one basic residue for another, one non-polar residue for another, one uncharged polar residue for another, or one aromatic residue for another, with the proviso that said third sequence is at least 90% identical to said first or second sequence.

29. The isolated polypeptide of

claim 28

, wherein said polypeptide comprises said first sequence.

30. The isolated polypeptide of

claim 28

, wherein said polypeptide comprises said second sequence.

31. The isolated polypeptide of

claim 28

, wherein said polypeptide comprises said third sequence.

32. The polypeptide of

claim 29

complexed to a ligand.

33. The polypeptide complex of

claim 32

, wherein said ligand is an antibody.

36. A reagent that specifically binds to the polypeptide of

claim 28

.

37. The reagent of

claim 36

, wherein said reagent is selected from the group consisting of monoclonal and polyclonal antibodies.

38. The reagent of

claim 36

, wherein said reagent is a physiological or synthetic ligand.

39. The polypeptide of

claim 28

, wherein said polypeptide in not glycosylated.

40. The polypeptide of

claim 28

, wherein said polypeptide is glycosylated.

48. A ligand for AC133 identified by the method of

claim 36

.

34. An isolated polypeptide, wherein said polypeptide comprises the amino acid sequence from extracellular N-terminus, aa 20-107;

first transmembrane region, aa 107-126;

first cytoplasmic loop, aa 127-157;

second transmembrane region, aa 158-179;

first extracellular loop, aa 180-435;

third transmembrane region, aa 436-454;

second cytoplasmic loop, aa 455-480;

fourth transmembrane region, aa 481-503;

second extracellular loop, aa 504-792;

fifth transmembrane, aa 793-816;

or cytoplasmic C-terminus, aa 817-865;

of SEQ ID NO;

2.

41. In a method of isolating hematopoietic stem cells using a cell separation technique based on identification of stem cells by selective binding of a ligand to an antigenic marker on said stem cell, an improvement which comprises:

utilizing an AC133 antigen as said antigenic marker.

42. The method of

claim 41

, wherein said ligand is an antibody.

43. The method of

claim 41

, wherein said ligand binds to an extracellular region of said AC133 antigen.

44. The method of

claim 41

, wherein said extracellular region comprises an amino acid selected from extracellular N-terminus, aa 20-107;

first extracellular loop, aa 180-435;

or second extracellular loop, aa 504-792;

of SEQ ID NO;

2.

45. The method of

claim 41

, wherein said ligand has been identified by determining whether compounds in a group of test compounds bind to said AC133 antigen and selecting said ligand from among compounds that bind specifically to said AC133 antigen with less than 10% crossreactivity with any antigen present on mature blood cells.

46. The method of

claim 41

, wherein crossreactivity is measured by a competitive binding assay between pure AC133 antigen, said ligand, and said suspected crossreactive antigen using concentrations of AC133 antigen and said ligand where said ligand half-saturates binding to AC133.

47. The method of

claim 41

, wherein crossreactivity is measured at a concentration of AC133 antigen that half saturates monoclonal antibody ATCC HB 12346 when said antibody is present at a concentration of 50 ng/100 μ

l.

49. A reagent that bind specifically to AC133 antigen with less than 5% crossreactivity with any antigen present on mature blood cells.

50. The reagent of

claim 49

, wherein said reagent is attached to a surface or to a detectible label.

51. The reagent of

claim 49

, wherein said label is a fluorescent label.